Loading
A phase 2 trial of Pyrotinib, Vinorelbine and Inetetamab in Breast cancer, run by Zhiyong Yu, with a status the registry has not verified recently.
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer is a phase 2 interventional study registered as NCT04963595 by Zhiyong Yu, with 100 participants planned, started 2021-08-01 and due to reach its primary completion in 2023-01-31. Interventions recorded: Pyrotinib, Vinorelbine, Inetetamab. Conditions recorded: Metastatic Breast Cancer.
Linked to the drug Inetetamab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Inetetamab, Pyrotinib, Breast cancer (all types) and the tag pipeline.
Shares Inetetamab, Breast cancer (all types) and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Shares Vinorelbine, Breast cancer (all types) and the tag pipeline.
Shares Vinorelbine and the tag pipeline.
Shares Vinorelbine and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/